476 related articles for article (PubMed ID: 28349386)
1. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Granhall C; Søndergaard FL; Thomsen M; Anderson TW
Clin Pharmacokinet; 2018 Dec; 57(12):1571-1580. PubMed ID: 29623579
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
Baekdal TA; Thomsen M; Kupčová V; Hansen CW; Anderson TW
J Clin Pharmacol; 2018 Oct; 58(10):1314-1323. PubMed ID: 29693715
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
Jensen L; Kupcova V; Arold G; Pettersson J; Hjerpsted JB
Diabetes Obes Metab; 2018 Apr; 20(4):998-1005. PubMed ID: 29205786
[TBL] [Abstract][Full Text] [Related]
5. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Granhall C; Donsmark M; Blicher TM; Golor G; Søndergaard FL; Thomsen M; Bækdal TA
Clin Pharmacokinet; 2019 Jun; 58(6):781-791. PubMed ID: 30565096
[TBL] [Abstract][Full Text] [Related]
6. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Bækdal TA; Breitschaft A; Navarria A; Hansen CW
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):869-877. PubMed ID: 29897249
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I; Jensen L; Flint A; Nishida T; Zacho J; Irie S
Adv Ther; 2018 Apr; 35(4):531-544. PubMed ID: 29536338
[TBL] [Abstract][Full Text] [Related]
10. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Hausner H; Derving Karsbøl J; Holst AG; Jacobsen JB; Wagner FD; Golor G; Anderson TW
Clin Pharmacokinet; 2017 Nov; 56(11):1391-1401. PubMed ID: 28349387
[TBL] [Abstract][Full Text] [Related]
11. Effect of renal impairment on the pharmacokinetics of exenatide.
Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
[TBL] [Abstract][Full Text] [Related]
12. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Bækdal TA; Borregaard J; Hansen CW; Thomsen M; Anderson TW
Clin Pharmacokinet; 2019 Sep; 58(9):1193-1203. PubMed ID: 30945118
[TBL] [Abstract][Full Text] [Related]
13. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
14. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
15. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
16. Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA; Crannage EF; Kerwin LC; Guyton JE
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.
Klein G; Petrone M; Yang Y; Hoang T; Hazlett S; Hansen L; Flor A
Clin Pharmacokinet; 2023 Jun; 62(6):881-890. PubMed ID: 37140727
[TBL] [Abstract][Full Text] [Related]
19. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
[TBL] [Abstract][Full Text] [Related]
20. Oral semaglutide in type 2 diabetes.
Anderson SL; Beutel TR; Trujillo JM
J Diabetes Complications; 2020 Apr; 34(4):107520. PubMed ID: 31952996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
